.jpg)
Custom VHH Antibody Discovery for Therapeutic Drug Monitoring (TDM) | YBL-Vega
Welcome
Progress is not how we grow; it is about how we make a difference in lives of others. This is our guiding principle at Yashraj Biotechnology Limited (YBL)
.JPG)
3
Background
Therapeutic Drug Monitoring (TDM) is essential for maintaining drug concentrations within a narrow therapeutic window to ensure efficacy and minimize toxicity. However, current immunoassays face a significant "TDM Inaccuracy" crisis. These assays often fail to distinguish between active antibiotics and their various degradation products, leading to clinical risks such as overestimated drug levels and incorrect patient dosing. There is a critical unmet need for highly specific antibodies that provide precise monitoring for next-generation immunodiagnostics.
Key Challenges
The primary technical hurdle is structural mimicry between the target drug and its metabolites.
- Specificity Gap: Conventional polyclonal and monoclonal antibodies struggle to differentiate between structurally similar molecules.
- Assay Failure: This lack of precision results in compromised specificity, which reduces clinical confidence in diagnostic results.
- Ethical & Speed Constraints: Traditional animal-based discovery methods often face ethical hurdles and slower development timelines.
Our Approach
- To overcome these barriers, Yashraj Biotechnology Ltd. (YBL) utilized the YBL-Vega Platform, a 100% animal-free antibody discovery solution.
- Synthetic VHH Library: We leveraged a highly diverse, NGS-verified synthetic camelid phage display (VHH) library containing $3\times10^3$ clones.
- Precision Engineering: Our team applied tailored bio-panning and rigorous counter-selection strategies to systematically eliminate cross-reactive binders.
- Differential Screening: We used advanced validation techniques to confirm that lead recombinant antibody candidates recognized only the active drug and ignored degradation products.
Results
The YBL-Vega platform successfully developed high-affinity custom antibodies in a VHH-Fc format, demonstrating robust, application-ready performance.
| Assay Type | Technical Performance | Diagnostic Impact |
|---|---|---|
| ELISA | Strong linearity with a broad dynamic range. | Sensitive and quantitative antigen detection. |
| Western & Dot Blot | Clear, linear signal detection across dilution series. | Reliable and consistent antigen recognition. |
| Flow Cytometry | Specific detection of cell-expressed surface antigens. | Validates performance on native targets in cellular contexts. |
Key Insight
The transition to synthetic VHH libraries (nanobodies) provides a definitive solution for hard-to-reach target epitopes that traditional IgG antibodies cannot access. By utilizing an animal-free, recombinant approach, diagnostic manufacturers can achieve absolute batch consistency, bypass ethical constraints, and significantly accelerate market entry with high-specificity reagents that directly enhance patient safety and clinical decision-making
